Clinical Trial Update: 1-Year Follow up to the 1473-IMIQ Study

View source ↗

Summary

The document provides the 1-year follow-up results from the 1473-IMIQ trial evaluating imiquimod for keratosis, sponsored by Graceway Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratosis

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: Graceway Pharmaceuticals, LLC | Conditions: Keratosis | Status: COMPLETED